News in brief
Success for Amgen as Europe welcomes first Avastin biosimilar
The European Commission has approved Mvasi, Amgen and Allergan's biosimilar version of Roche’s cancer drug Avastin (bevacizumab).
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs